Efruxifermin Publications
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Harrison, S. et al. (2021) Nature Medicine
Efruxifermin is Associated With Improved Glucose Metabolism in Patients With NASH and Type 2 Diabetes
Frias, J. et al. (2021) ADA Scientific Sessions
Increased adiponectin following efruxifermin treatment is associatedwith improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NASH
Frias, J. et al. (2021) ADA Scientific Sessions
Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, and metabolism, and in histologic parameters following treatment with efruxifermin
Harrison, S. et al. (2021) EASL
The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial
Loomba, R. et al. (2021) EASL
AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients
Kaufman, A. et al. (2020) Cell Rep Med
Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase
Byun, S. et al. (2020) Nat. Commun
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
Hatlen, M. et al. (2019) Cancer Discov
LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice
Le CT et al. (2018) PLOS ONE
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Sanyal A et al. (2018) Lancet
FGF21 gene therapy as treatment for obesity and insulin resistance
Jimenez V et al. (2018) EMBO Mol Med
A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling
Shi S et al. (2018) Sci Rep
A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway
Bao L et al. (2018) British J Pharmacol
Recent advances in understanding and managing non-alcoholic fatty liver disease
Albhaisi S and Sanyal A (2018) F1000Res
FGF21 acts as a negative regulator of bile acid synthesis
Chen MM et al. (2018) J Endocrinol
Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signaling
Lee S et al. (2018) Nature
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Estes C et al. (2018) Hepatol
A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys
Stanislaus S et al. (2017) Endocrinol
FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists
Li X et al. (2017) J Bone Miner Res
Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury
Desai BN et al. (2017) Mol Metab
Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway
Yu Y et al. (2016) Int. Immunopharmacol
An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function
Lee JH et al. (2016) Am J Translational Res
Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways
Xu P et al. (2016) Toxicol & Applied Pharmacol
Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders
Zhang J et al. (2015) Front Endocrinol
Fibroblast Growth Factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets
Fisher FM et al. (2014) Gastroenterology
Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions
Ge, H et al. (2014) J Biol Chem
Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice
Yu X et al. (2013) PLOS ONE
Published Amgen synopses of AKR-001 Phase 1 clinical trials
Amgen (2013/2015) Amgen Clinical Trials
Dual actions of fibroblast growth factor 19 on lipid metabolism
Wu X et al. (2013) J Lipid Res
Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models–association with liver and adipose tissue effects
Xu et al. (2009) Am J Physiol Endocrinol Metab
Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice
Wu X et al. (2009) Proc Natl Acad Sci USA
Fibroblast Growth Factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice
Xu J et al. (2009) Diabetes
FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver
Huang X et al. (2007) Diabetes
The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.
Kharitonenkov A et al. (2007) Endocrinol